Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 8/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16513000 | 0.91 | PTGES (0.46) | RECQLKDM4EPTGS1KCNK3KCNK9 | |
| SCHEMBL16512729 | 0.85 | GRM4 (0.45) | KDM4EPTGS1KCNK3KCNK9TP53 | |
| SCHEMBL16372428 | 0.81 | KDM4E (0.51) | RECQLKDM4EGRM5PTGS1KCNK3 | |
| SCHEMBL16371764 | 0.78 | GAA (0.48) | RECQLKDM4EGRM5PTGS1KCNK3 | |
| SCHEMBL16486751 | 0.76 | LMNA (0.48) | PTGS1KCNK3KCNK9TP53LMNA | |
| SCHEMBL16392354 | 0.72 | PTPRC (0.48) | RECQLPTGS1KCNK3KCNK9TP53 | |
| SCHEMBL16711799 | 0.70 | ALDH1A1 (0.51) | KDM4EGRM5LMNAGAAPTGES | |
| SCHEMBL727891 | 0.70 | GLA (0.47) | KDM4ETP53LMNAGAAPTGES | |
| SCHEMBL16372308 | 0.70 | LMNA (0.59) | RECQLPTGS1KCNK3KCNK9TP53 | |
| SCHEMBL16371758 | 0.70 | LMNA (0.55) | RECQLKDM4EPTGS1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| EP-3033330-B1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| EP-3033330-A2 | NOVEL COMPOUNDS | Syngenta Participations AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022265-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022265-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176806-A1 | NOVEL COMPOUNDS | SGMS1, DDT, CYP1B1 | RECQL 3476/4885KDM4E 1588/4885GRM5 3189/4885 |
| US-10207985-B2 | Compounds | CYP1B1, DDT, CYP1A1 | RECQL 3291/4885KDM4E 1903/4885GRM5 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.